Ensysce Biosciences Narrows Loss in Q2

Ensysce Biosciences (NASDAQ:ENSC), a biotechnology company developing abuse-deterrent opioid therapies, reported its second-quarter results on August 13, 2025. The quarter’s biggest news included the launch of a pivotal Phase 3 clinical trial for its lead program, PF614, and full enrollment in a key study of its PF614-MPAR overdose-protection candidate. Financially, the quarter fell short of expectations. The company reported a GAAP loss per share of $(0.79), beating analysts’ estimates of $(1.01). Revenue, all from federal grants, was $1.37 million, more than double the year-ago period. Despite research progress, the net loss and continued absence of commercial revenue signal ongoing financial pressure for the company. Source: Analyst estimates for the quarter provided by FactSet. Ensysce Biosciences is a biotech company focused on developing safer opioid painkillers. Its main goal is to address the opioid misuse crisis through advanced drug formulations that deter abuse while retaining pain-relief effectiveness. The company’s lead candidates are built on two platforms: Trypsin-Activated Abuse Protection (TAAP), which only releases the opioid drug when swallowed and exposed to digestive enzymes, and the Multi-Pill Abuse Resistant (MPAR) system, designed to reduce overdose risks.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool